Fig. 1. *In vitro* potency determination curves of 4-(3,5-Bis-[(S)-2-eth-(E)-ylidene-7-methoxy-1,2,3,11a-tetrahydro- pyrrolo[2,1c][1,4] benzodiazepin-5-one-8-yloxymethyl]-phenoxy)-butyric acid methyl ester of ex. 1.




Fig. 2. *In vitro* potency determination curves of 4-(3,5-Bis-[(S)-2-eth-(E)-ylidene-7-methoxy-1,2,3,11a-tetrahydro-pyrrolo[2,1c][1,4] benzodiazepin-5-one-8-yloxymethyl]-phenoxy)-acetic acid methyl ester of ex. 2





Fig. 3. ***In vitro*** **potency determination curves of compounds 8 (IGP08) and 9 (IGP08-OMe) of example 8 showing higher potency for ester IGP08-OMe than for acid IGP08**






Fig. 4. MS (mass spectral) analysis of deglycosylated huMy9-6 - 4-(3,5-Bis-[(S)-2-eth-(E)-ylidene-7-methoxy-1,2,3,11a-tetrahydro-pyrrolo[2,1c][1,4] benzodiazepin-5-one-8-yloxymethyl]-phenoxy)-butyryl conjugate (2.1 Drug/Ab by UV) of ex. 11




Fig. 5. MS analysis of deglycosylated huB4- 4-(3,5-Bis-[(S)-2-eth-(E)-ylidene-7-methoxy-1,2,3,11a-tetrahydro-pyrrolo[2,1c][1,4] benzodiazepin-5-one-8-yloxymethyl]-phenoxy)-butyryl conjugate (4.48 D/A by UV) of ex. 12




Fig. 6. MS analysis of deglycosylated hu2H11- 4-(3,5-Bis-[(S)-2-eth-(E)-ylidene-7-methoxy-1,2,3,11a-tetrahydro-pyrrolo[2,1c][1,4] benzodiazepin-5-one-8-yloxymethyl]-phenoxy)-butyryl conjugate (3.74 D/A by UV) of ex. 13




Fig. 7. MS analysis of deglycosylated huMy9-6 - 3-(2-{2-[2-(3,5-Bis-[(S)-2-eth-(E)-ylidene-7-methoxy-1,2,3,11a-tetrahydro-pyrrolo [2,1c][1,4]benzodiazepin-5-one-8-yloxymethyl]-phenoxy)-ethoxy]-ethoxy}-ethoxy)-propionyl conjugate (4.80 D/A by UV) of ex. 14





Fig. 8. MS analysis of deglycosylated hu2H11 - 3-(2-{2-[2-(3,5-Bis-[(S)-2-eth-(E)-ylidene-7-methoxy-1,2,3,11a-tetrahydro-pyrrolo [2,1c][1,4]benzodiazepin-5-one-8-yloxymethyl]-phenoxy)-ethoxy]-ethoxy}-ethoxy)-propionyl conjugate (4.08 D/A by UV) of ex. 15



D0 D1 D2 D3 D4 D5 D6

Figure 9. Mass spectral analysis of deglycosylated huMy9-6-IGP08; (Drugs/Antibody = 4.2) of example 18






Fig. 10. Binding of huMY9-6 antibody and huMY9-6-IGP08 Conjugate to CD33 antigen of ex. 18



Conjugate/antibody	EC 50
huMY9-6-IGP08	6.631e-10 M
huMY9-6 antibody	3.073e-10 M

Fig. 11. Cytotoxicity Data of My9-6-IGP08 on HL60/QC (Ag+) and Ramos (Ag-) Cells



Conjugate	(nM)	
	HL60/QC	Ramos
My9-6-IGP-08	0.0029	11

Fig. 12. MS analysis of deglycolylated huB4-IGP08 of ex. 19






Fig. 13. Cytotoxicity: huB4-IGP08 (3.1 D/A) vs. BJAB (Ag+), Ramos (Ag+) & MOLT-4 (Ag-) cells



~IC_{50}'s

BJAB cells	< 7.6e-13 M
Ramos cells	< 7.6e-13 M
MOLT-4 cells	> 5.0e-9 M

Fig. 14. Binding of hu-B4 antibody and huB4-IGP08 conjugate of example 19



Conjugate/antibody	EC 50
huB4-IGP08	7.779e-11 M
huB4 antibody	4.598e-11 M

Fig. 15. MS analysis of deglycosylated hu2H11-IGP-13 (4.7 D/A by UV) of ex. 21





Fig. 16. In vitro cytotoxicity data for hu2H11-IGP-13 with increasing drug loads on PC-3 (Ag+), MDA-MB-231 (Ag+), and SK-MEL-28 (Ag-) cell lines



Conjugate	IC50		
	PC-3	MDA-MB-231	SK-MEL-28
hu2H11-IGP13 (2.1 D/A)	6.0e-12 M	6.0e-12 M	1.8e-8 M
hu2H11-IGP13 (3.2 D/A)	4.0e-12 M	5.0e-12 M	1.8e-8 M
hu2H11-IGP13 (4.0 D/A)	3.5e-12 M	4.5e-12 M	5.3e-9 M
hu2H11-IGP13 (4.7 D/A)	2.5e-12 M	2.5e-12 M	3.4e-9 M

Fig.17. *In vitro* cytotoxicity data for 3-(2-{2-[2-(2,6-Bis-[(S)-2-eth-(E)-ylidene-7-methoxy-1,2,3,11a-tetrahydro-pyrrolo[2,1c][1,4]benzodiazepin-5-one-8-yloxymethyl]-pyridin-4-yloxy)-ethoxy]-ethoxy}-ethoxy)-propionic acid methyl ester from ex. 5




Fig.18. *In vitro* cytotoxicity data for 4-(2,6-Bis-[(S)-2-eth-(E)-ylidene-7-methoxy-1,2,3,11a-tetrahydro-pyrrolo[2,1c][1,4]benzodiazepin-5-one-8-yloxymethyl]-pyridin-4-yloxy)-butyric acid methyl ester from ex. 6




Fig. 19. *In vitro* cytotoxicity data for N-[2-(3,5-Bis-[(S)-2-eth-(E)-ylidene-7-methoxy-1,2,3,11a-tetrahydro-pyrrolo[2,1c][1,4]benzodiazepin-5-one-8-yloxymethyl]-phenoxy)-ethyl]-N-methyl-succinamic acid methyl ester from ex. 7






Fig. 20. *In vitro* cytotoxicity data for huMy9-6 - 4-(3,5-Bis-[(S)-2-eth-(E)-ylidene-7-methoxy-1,2,3,11a-tetrahydro-pyrrolo[2,1c][1,4]benzodiazepin-5-one-8-yloxymethyl]-phenoxy)-butyryl conjugate from ex. 11 on HL60/ATCC (Ag+) and Ramos (Ag-) cells




	IC_{50}, M
HL60/ATCC*	$7.2\ 10^{-12}$
Ramos^	$>5\ 10^{-9}$
Selectivity	>694x

Fig. 21: *In vitro* cytotoxicity data for huB4 - 4-(3,5-Bis-[(S)-2-eth-(E)-ylidene-7-methoxy-1,2,3,11a-tetrahydro-pyrrolo[2,1c][1,4]benzodiazepin-5-one-8-yloxymethyl]-phenoxy)-butyryl conjugate from ex. 12 on Ramos (Ag+) and MOLT-4 (Ag-) cells



Ramos cells	< 5.0e-13 M
MOLT-4 cells	6.4e-10 M

Fig. 22 *In vitro* cytotoxicity data for hu2H11 - 4-(3,5-Bis-[(S)-2-eth-(E)-ylidene-7-methoxy-1,2,3,11a-tetrahydro-pyrrolo[2,1c][1,4]benzodiazepin-5-one-8-yloxymethyl]-phenoxy)-butyryl conjugate from example 13 on MDA-MB-231 (Ag+), PC-3 (Ag+) and SK-MEL-28 (Ag-) cells



MDA-MB-231 cells	5.4e-13 M
PC-3 cells	1.2e-12 M
SK-MEL-28 cells	> 3.0e-9 M

Fig. 23 *In vitro* cytotoxicity data for huMy9-6 - 3-(2-{2-[2-(3,5-Bis-[(S)-2-eth-(E)-ylidene-7-methoxy-1,2,3,11a-tetrahydro-pyrrolo[2,1c][1,4]benzodiazepin-5-one-8-yloxymethyl]-phenoxy)-ethoxy]-ethoxy}-ethoxy)-propionyl conjugate from ex. 14 on HL60/ATCC (Ag+) and Ramos (Ag-) cells




Fig. 24 *In vitro* cytotoxicity data for hu2H11 - 3-(2-{2-[2-(3,5-Bis-[(S)-2-eth-(E)-ylidene-7-methoxy-1,2,3,11a-tetrahydro-pyrrolo[2,1c][1,4]benzodiazepin-5-one-8-yloxymethyl]-phenoxy)-ethoxy]-ethoxy}-ethoxy)-propionyl conjugate from ex. 15 on MDA-MB-231 (Ag+), PC-3 (Ag+) and SK-MEL-28 (Ag-) cells

